Scientific Data Presentations
Explore Thryv Therapeutics’ scientific presentations spanning our research programs in Long QT Syndrome, heart failure, atrial fibrillation, and fibrosis.
Thryv at AHA Basic Cardiovascular Sciences Scientific Sessions 2026!
Poster Presentation · Wednesday, July 15, 2026 · 4:30 PM
Back Bay & Republic Ballroom
New preclinical data on SGK1 inhibition
Long QT Syndrome (LQTS) Scientific Presentations
SGK-1 INHIBITION WITH LQT-1213 SIGNIFICANTLY REDUCES THE QTCF IN PATIENTS WITH CONGENITAL LONG QT SYNDROME IN THE WAVE I, PART 2 STUDY
Heart Rhythm Society Annual Meeting — San Diego, CA | April 2025
SGK1 INHIBITION SHORTENS ACTION POTENTIAL DURATION IN LQT3 MICE AND LQT2 RABBITS VIA INHIBITION OF LATE SODIUM CURRENT
American Heart Association Scientific Sessions — Chicago, IL | November 2024
ATTENUATION OF DRUG-INDUCED QT-PROLONGATION IN GUINEA PIG ISOLATED HEART AND ANESTHETIZED DOG MODELS OF DRUG-INDUCED QT PROLONGATION BY SERUM/GLUCOCORTICOID REGULATED KINASE 1 (SGK-1) INHIBITORS
Heart Rhythm Society Conference — Boston, MA | May 2024
SGK-1 INHIBITOR ATTENUATES QTCF PROLONGATION IN A DOFETILIDE-INDUCED HUMAN MODEL (WAVE I CLINICAL STUDY)
American College of Cardiology Conference — Atlanta, GA | March 2024
SGK1 INHIBITION ATTENUATED THE ACTION POTENTIAL DURATION IN PATIENT- AND GENOTYPE-SPECIFIC RE-ENGINEERED HEART CELLS WITH CONGENITAL LONG QT SYNDROME
American Heart Association Scientific Sessions — Chicago, IL | November 2022
SGK1 INHIBITION AND ATTENUATION OF ACTION POTENTIAL DURATION IN RE-ENGINEERED HEART CELL MODELS OF DRUG-INDUCED QT PROLONGATION
American Heart Association Scientific Sessions — Chicago, IL | November 2022
Heart Failure (HF) Scientific Presentations
SMALL MOLECULE INHIBITORS OF SERUM GLUCOCORTICOID KINASE 1 (SGK1) PREVENT CARDIAC STRUCTURAL AND FUNCTIONAL DECLINE IN A TRANSVERSE AORTIC CONSTRICTION (TAC) MODEL
American Heart Association Scientific Sessions — New Orleans, LA | November 2025
THRV-1268, A POTENT AND SELECTIVE SERUM AND GLUCOCORTICOID REGULATED KINASE (SGK1) INHIBITOR, IMPROVES ADVERSE CARDIAC REMODELING BETTER THAN JARDIANCE® (EMPAGLIFLOZIN), A SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITOR IN HEART FAILURE
American Heart Association Scientific Sessions — New Orleans, LA | November 2025
THE SERUM AND GLUCOCORTICOID REGULATED KINASE 1 (SGK1) INHIBITOR THRV-1268 ATTENUATES HALLMARKS OF HEART FAILURE BY REDUCING INFLAMMATION AND FIBROSIS BEYOND SODIUM/GLUCOSE COTRANSPORTER 2 INHIBITION
American Heart Association Scientific Sessions — New Orleans, LA | November 2025
THRV-1268, A NOVEL AND POTENT SGK1 INHIBITOR, IMPROVED ADVERSE CARDIAC REMODELING BEYOND EMPAGLIFLOZIN, AN SGLT2 INHIBITOR, BY REDUCING INFLAMMATION AND FIBROSIS MECHANISMS IN HEART FAILURE
European Society of Cardiology (ESC) Congress — Madrid, Spain | August 2025
SERUM GLUCOCORTICOID REGULATED KINASE 1 (SGK-1) INHIBITOR REDUCED HYPERTENSION IN A SALT-SENSITIVE HYPERTENSION MODEL OF HEART FAILURE WITH PRESERVED EJECTION FRACTION
American Heart Association Scientific Sessions — Chicago, IL | November 2024
SGK1 INHIBITION ATTENUATED LEFT VENTRICULAR THICKENING AND DIASTOLIC DYSFUNCTION IN A MOUSE MODEL OF HFPEF
American Heart Association Scientific Sessions — Chicago, IL | November 2024
Atrial Fibrillation (AF) Scientific Presentations
A NOVEL SGK1 INHIBITOR (SGK1-I) PREVENTS OBESITY-RELATED ATRIAL FIBRILLATION
American Heart Association Scientific Sessions — Philadelphia, PA | November 2023
Fibrosis Scientific Presentations
SERUM AND GLUCOCORTICOID REGULATED KINASE 1 (SGK1) INHIBITION INDUCES ANTI-FIBROTIC AND ANTI-INFLAMMATORY RESPONSES: RELEVANCE TO CARDIAC FIBROSIS
American Heart Association Scientific Sessions — Chicago, IL | November 2024